Sibnayal® (ADV6209)

About Advicenne

Advicenne is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for orphan renal and neurological diseases, with a strong emphasis on pediatric-friendly formulations. Its primary achievement is the European approval and commercial launch of Sibnayal® for dRTA, with a significant near-term catalyst being the FDA's review of its New Drug Application (NDA) for the same indication. The company's strategy leverages orphan drug designations and strategic partnerships to establish commercial footholds in niche markets with high unmet medical need, aiming to build a sustainable, specialty-focused business.

Therapeutic Areas